EGFR and non-small cell lung carcinoma: The systematic review and network meta-analysis conducted by Chan and colleagues in 2022 focused on the potential beneficial effects of first-line therapies on OS timeframes within advanced epidermal growth factor receptor (EGFR) mutated NSCLC Asian patient cohorts carrying the L858R mutation [23].